Holen Sie sich die Stockscreener-App
107.81
0.14%
-0.15
Handel nachbörslich:
107.66
-0.15
-0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$107.96
Offen:
$107.03
24-Stunden-Volumen:
6.57M
Relative Volume:
0.50
Marktkapitalisierung:
$187.78B
Einnahmen:
$46.59B
Nettoeinkommen (Verlust:
$5.41B
KGV:
34.85
EPS:
3.0938
Netto-Cashflow:
$7.38B
1W Leistung:
+1.96%
1M Leistung:
+12.49%
6M Leistung:
-2.72%
1J Leistung:
-18.36%
1-Tages-Spanne:
$106.01
$107.97
1-Wochen-Bereich:
$104.20
$109.33
52-Wochen-Spanne:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
107.81 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.03 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
87.16 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.31 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.72 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends - TradingView
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance - GlobeNewswire Inc.
FRAUD AND MANIPULATION—N.D. Ill.: Abbott did not commit securities fraud over tainted baby formula - VitalLaw.com
Abbott (ABT) Lands Exclusive Rights To FDA Approved Blood Based CRC Test - Yahoo Finance
Freenome went public for $300 million, then scored a huge victory with colorectal cancer test - The Business Journals
Abbott (ABT) Raised Its Profit Forecast. What’s Driving Its Growth? - Yahoo Finance
Federal Judge Dismisses Abbott Shareholder Lawsuit Over 2022 Infant Formula Recall - Law Commentary
Abbott Labs Shakes Investor Suit Over 2022 Infant Formula Recall - Bloomberg Law News
FDA approves Freenome colorectal cancer blood test to be marketed by Abbott - Fierce Biotech
FDA approves Freenome's blood test for colorectal cancer screening - Reuters
Is Abbott Stock Attractive After Its Earnings and Guidance Update? - The Globe and Mail
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. - BioSpace
Abbott (ABT) Introduces FDA-Approved SimpleScreen CRC for Colore - GuruFocus
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth - Yahoo Finance
Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson - The Globe and Mail
Why Is Abbott Laboratories (NYSE:ABT) a Blue-Chip Stock to Watch? - Kalkine Media
Abbott stock trades steady as investors weigh recent earnings and medical device growth - Ad-hoc-news.de
Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings - Ad-hoc-news.de
PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records - Los Angeles Downtown News
Abbott Laboratories (ABT) Could Be 14% Undervalued On Mixed Earnings And Growth Focus - simplywall.st
Abbott defeats shareholder lawsuit over 2022 infant formula recall | Business Information & News | FE - Westlaw Today
Health News Roundup: Abbott Wins Lawsuit, Measles Surge in the US, and More Updates - Devdiscourse
Abbott Beats 'Supersized' Investor Suit Over Formula Recall - Law360
Abbott Wins 7th Circ. Fight Over Baby Formula Warning - Law360
Patient Sues Abbott Labs, Exact Sciences in Data Theft - BankInfoSecurity
Abbott Notches Appellate Win in Bellwether Infant Formula Case - news.bloombergtax.com
Abbott defeats shareholder lawsuit over 2022 infant formula recall - Reuters
Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher - TradingView
FreeStyle Libre 3 Class Action Lawsuit Alleges Abbott Sold Defective Glucose Monitors - AboutLawsuits.com
Medtech Stocks Have Gotten Slammed. Why Abbott, Danaher, 4 More Are Bargains. - Barron's
Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum - AD HOC NEWS
Abbott Laboratories and Exact Sciences Corp Under Investigation for Data Breach of Patient Records - Schubert Jonckheer & Kolbe
Abbott Labs Accused Of Lax Security Over Shinyhunters Hack - Law360
Abbott Stock And 2 Dividend Ideas For Retirement Income - simplywall.st
ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now? - TradingView
Abbott Faces Spine Stimulator Lawsuit Brought Jointly by 17 Injured Patients - AboutLawsuits.com
Abbott Laboratories (NYSE:ABT) Faces A Profit Test - Kalkine Media
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating - marketscreener.com
Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not - Trefis
Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026 - simplywall.st
Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value? - Yahoo Finance
Abbott Laboratories stock holds gains after strong diagnostics and medical devices momentum - Ad-hoc-news.de
Abbott Laboratories (ABT) Stock Forecasts - Yahoo Finance
Abbott (NYSE:ABT) Faces A Crucial Valuation Test - Kalkine Media
Leerink Partners Adjusts Price Target on Abbott Laboratories to $109 From $106, Maintains Market Perform Rating - marketscreener.com
Cancer Diagnostics Breached At Abbott As 2026 Medtech Cyberattack Run Continues - insights.citeline.com
Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades - simplywall.st
Abbott Laboratories stock steadies as medical devices and diagnostics underpin growth - Ad-hoc-news.de
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Patients sue diagnostics company over data breach - Courthouse News
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories - Yahoo Finance
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):